Thoracic Research and Practice
Original Article

Charlson Comorbidity Index in Predicting Poor Clinical Outcomes and Mortality in Patients with COVID-19

1.

Department of Pulmonary Diseases, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey

2.

Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey

Thorac Res Pract 2022; 23: 145-153
DOI: 10.5152/TurkThoracJ.2022.21076
Read: 1145 Downloads: 434 Published: 01 March 2022

OBJECTIVE: As known, older age and comorbidities are associated with poor clinical outcomes in patients with coronavirus disease 19. The aim of this study was to investigate the effect of the Charlson Comorbidity Index in predicting poor clinical outcomes in coronavirus disease 19 patients.

MATERIAL AND METHODS: Demographic characteristics and poor clinical outcomes (presence of pneumonia, respiratory failure, intensive care unit admission, and mortality) of the patients were evaluated retrospectively. Classical and modified Charlson Comorbidity Index was calculated and adjusted according to age.

RESULTS: In this study, 106 women and 107 men were included. The comorbidity rate was 50.7% and the most common comorbidities were hypertension (21.6%) and diabetes mellitus (15%). The rates of respiratory failure, intensive care unit admission, and mortality were 15%, 2.3%, and 2.8%, respectively. Older age was a high risk for poor outcomes. Pneumonia (odds ratio: 6.6; 95% CI: 3.4-12.7), respiratory failure (odds ratio: 5.2; 95% CI: 2.03-13.2), and intensive care unit admission (odds ratio: 1.1; 95% CI: 1.01-1.1) were significantly higher in patients with comorbid diseases than patients without any comorbidity (P < .05). Both median-modified and classical Charlson Comorbidity Index and their age-adjusted scores were significantly higher in patients with poor outcomes.

CONCLUSIONS: It is suggested that evaluation of the Charlson Comorbidity Index might contribute to the management of the patients with coronavirus disease 19 by predicting risk group for poor clinical outcomes and mortality.

Cite this article as: Argun Barış S, Boyacı H, Akhan S, Mutlu B, Deniz M, Başyiğit İ. Charlson comorbidity index in predicting poor clinical outcomes and mortality in patients with COVID-19. Turk Thorac J. 2022;23(2):145-153.

Files
EISSN 2979-9139